319 related articles for article (PubMed ID: 22069374)
21. Regulation of cellular and humoral immune responses by the SLAM and SAP families of molecules.
Ma CS; Nichols KE; Tangye SG
Annu Rev Immunol; 2007; 25():337-79. PubMed ID: 17201683
[TBL] [Abstract][Full Text] [Related]
22. The X-linked lymphoproliferative-disease gene product SAP regulates signals induced through the co-receptor SLAM.
Sayos J; Wu C; Morra M; Wang N; Zhang X; Allen D; van Schaik S; Notarangelo L; Geha R; Roncarolo MG; Oettgen H; De Vries JE; Aversa G; Terhorst C
Nature; 1998 Oct; 395(6701):462-9. PubMed ID: 9774102
[TBL] [Abstract][Full Text] [Related]
23. Increased lymphocyte viability after non-stimulated peripheral blood mononuclear cell (PBMC) culture in patients with X-linked lymphoproliferative disease (XLP).
Belmonte L; Parodi C; Bastón M; Coraglia A; Felippo M; Baré P; Malbrán A; Ruibal-Ares B; de E de Bracco MM
Clin Immunol; 2009 Oct; 133(1):86-94. PubMed ID: 19576857
[TBL] [Abstract][Full Text] [Related]
24. X-linked lymphoproliferative syndromes and related autosomal recessive disorders.
Veillette A; Pérez-Quintero LA; Latour S
Curr Opin Allergy Clin Immunol; 2013 Dec; 13(6):614-22. PubMed ID: 24113228
[TBL] [Abstract][Full Text] [Related]
25. Role of SLAM-associated protein in the pathogenesis of autoimmune diseases and immunological disorders.
Furukawa H; Tohma S; Kitazawa H; Komori H; Nose M; Ono M
Arch Immunol Ther Exp (Warsz); 2010 Feb; 58(1):37-44. PubMed ID: 20049647
[TBL] [Abstract][Full Text] [Related]
26. Missense mutations in SH2D1A identified in patients with X-linked lymphoproliferative disease differentially affect the expression and function of SAP.
Hare NJ; Ma CS; Alvaro F; Nichols KE; Tangye SG
Int Immunol; 2006 Jul; 18(7):1055-65. PubMed ID: 16720617
[TBL] [Abstract][Full Text] [Related]
27. Activation-dependent T cell expression of the X-linked lymphoproliferative disease gene product SLAM-associated protein and its assessment for patient detection.
Shinozaki K; Kanegane H; Matsukura H; Sumazaki R; Tsuchida M; Makita M; Kimoto Y; Kanai R; Tsumura K; Kondoh T; Moriuchi H; Miyawaki T
Int Immunol; 2002 Oct; 14(10):1215-23. PubMed ID: 12356686
[TBL] [Abstract][Full Text] [Related]
28. Defective NK cell activation in X-linked lymphoproliferative disease.
Benoit L; Wang X; Pabst HF; Dutz J; Tan R
J Immunol; 2000 Oct; 165(7):3549-53. PubMed ID: 11034354
[TBL] [Abstract][Full Text] [Related]
29. X-linked lymphoproliferative disease is caused by deficiency of a novel SH2 domain-containing signal transduction adaptor protein.
Schuster V; Kreth HW
Immunol Rev; 2000 Dec; 178():21-8. PubMed ID: 11213803
[TBL] [Abstract][Full Text] [Related]
30. X-linked lymphoproliferative disease: a progressive immunodeficiency.
Morra M; Howie D; Grande MS; Sayos J; Wang N; Wu C; Engel P; Terhorst C
Annu Rev Immunol; 2001; 19():657-82. PubMed ID: 11244050
[TBL] [Abstract][Full Text] [Related]
31. Association of the X-linked lymphoproliferative disease gene product SAP/SH2D1A with 2B4, a natural killer cell-activating molecule, is dependent on phosphoinositide 3-kinase.
Aoukaty A; Tan R
J Biol Chem; 2002 Apr; 277(15):13331-7. PubMed ID: 11815622
[TBL] [Abstract][Full Text] [Related]
32. [Two families of X-linked lymphoproliferative disease type 1 characterized by agammaglobulinemia].
Li WY; Chen JS; Zhao Q; Dai RX; Wang YP; Zhao HY; Chen XM; Xue XH; Sun XY; Tang XM; Zhang Y; Ding Y; Zhao XD; Zhang ZY
Zhonghua Er Ke Za Zhi; 2017 May; 55(5):377-382. PubMed ID: 28482391
[No Abstract] [Full Text] [Related]
33. 2B4-SAP signaling is required for the priming of naive CD8
Huang YH; Tsai K; Tan SY; Kang S; Ford ML; Harder KW; Priatel JJ
Oncoimmunology; 2017; 6(2):e1267094. PubMed ID: 28344876
[TBL] [Abstract][Full Text] [Related]
34. Molecular and cellular pathogenesis of X-linked lymphoproliferative disease.
Nichols KE; Ma CS; Cannons JL; Schwartzberg PL; Tangye SG
Immunol Rev; 2005 Feb; 203():180-99. PubMed ID: 15661030
[TBL] [Abstract][Full Text] [Related]
35. NTB-A [correction of GNTB-A], a novel SH2D1A-associated surface molecule contributing to the inability of natural killer cells to kill Epstein-Barr virus-infected B cells in X-linked lymphoproliferative disease.
Bottino C; Falco M; Parolini S; Marcenaro E; Augugliaro R; Sivori S; Landi E; Biassoni R; Notarangelo LD; Moretta L; Moretta A
J Exp Med; 2001 Aug; 194(3):235-46. PubMed ID: 11489943
[TBL] [Abstract][Full Text] [Related]
36. 2B4: an NK cell activating receptor with unique specificity and signal transduction mechanism.
Nakajima H; Colonna M
Hum Immunol; 2000 Jan; 61(1):39-43. PubMed ID: 10658976
[TBL] [Abstract][Full Text] [Related]
37. X-linked lymphoproliferative syndrome: a genetic condition typified by the triad of infection, immunodeficiency and lymphoma.
Rezaei N; Mahmoudi E; Aghamohammadi A; Das R; Nichols KE
Br J Haematol; 2011 Jan; 152(1):13-30. PubMed ID: 21083659
[TBL] [Abstract][Full Text] [Related]
38. Correlation of mutations of the SH2D1A gene and epstein-barr virus infection with clinical phenotype and outcome in X-linked lymphoproliferative disease.
Sumegi J; Huang D; Lanyi A; Davis JD; Seemayer TA; Maeda A; Klein G; Seri M; Wakiguchi H; Purtilo DT; Gross TG
Blood; 2000 Nov; 96(9):3118-25. PubMed ID: 11049992
[TBL] [Abstract][Full Text] [Related]
39. A spectrum of mutations in SH2D1A that causes X-linked lymphoproliferative disease and other Epstein-Barr virus-associated illnesses.
Sumegi J; Seemayer TA; Huang D; Davis JR; Morra M; Gross TG; Yin L; Romco G; Klein E; Terhorst C; Lanyi A
Leuk Lymphoma; 2002 Jun; 43(6):1189-201. PubMed ID: 12152986
[TBL] [Abstract][Full Text] [Related]
40. Molecular and immunological basis of X-linked lymphoproliferative disease.
Latour S; Veillette A
Immunol Rev; 2003 Apr; 192():212-24. PubMed ID: 12670406
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
